ZN
Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
$3.08 -3.14% (-$0.10)
1M -19.37%
Market Cap $219.3M
P/E Ratio -
Div. Yield -
ROE 87.95%
Bulios Fair Price
$2.79
9.4% downside
Current Price
$3.08
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ZNTL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
99 /100
Cheap P/B 1.53x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 20.72%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 105.66%
ROE 87.95%
ROA 81.22%
Debt
100 /100
Low Debt/Equity 0.26x
Current ratio 4.82x
Int. coverage N/A
Stability
35 /100
Moderate Beta 1.86x
EPS volatility 24.08%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ZNTL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Julia Marie Eastland
Employees
106
Headquarters
San Diego
Upcoming events
10 NOV
Earnings
Upcoming earnings report